Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors

Anti-Cancer Drugs

Volumn 24, Issue 4, 2013, Pages 415-421

  Coulter, Don W ^f   Walko, Christine ^b   Patel, Jai ^b   Moats Staats, Billie M ^a   Mcfadden, Andrew ^b,d   Smith, Scott V ^a   Khan, Wasiuddin A ^b   Bridges, Arlene S ^a   Deal, Allison M ^b,c   Oesterheld, Javier ^e   Davis, Ian J ^a,b,d   Blatt, Julie ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

^d University of Nebraska ^*  (United States)

^e Levine Children's Hospital   (United States)

^f UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

pediatrics; phase I; solid tumors; temsirolimus; valproic

Indexed keywords

DIPHENHYDRAMINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; TEMSIROLIMUS; TUMOR MARKER; VALPROIC ACID;

ACNE; ADOLESCENT; ADULT; ALVEOLAR SOFT PART SARCOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER TISSUE; CHEMOTHERAPY INDUCED ANEMIA; CHILD; CHILDHOOD CANCER; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EPENDYMOMA; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFUSION RELATED REACTION; LIVER CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; SCHOOL CHILD; SOLID TUMOR; SPINAL CORD TUMOR; THORAX PAIN; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TREATMENT RESISTANT DEPRESSION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DIPHENHYDRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; EARLY TERMINATION OF CLINICAL TRIALS; FATIGUE; FEMALE; HEMATOLOGIC DISEASES; HISTONE DEACETYLASE INHIBITORS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MUCOSITIS; NEOPLASMS; PAIN; SIROLIMUS; VALPROIC ACID;

EID: 84875052868     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835dc7c5     Document Type: Article

References (26)

1. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281
2. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, et al. Phase II trial of single-Agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347-5356
3. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-5322
4. Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: A study of the Mayo phase 2 consortium (P2C). Cancer 2011; 117:3468-3475
5. Italiano A, Kind M, Stoeckle E, Jones N, Coindre JM, Bui B. Temsirolimus in advanced leiomyosarcomas:Patterns of response and correlation with the activation of the mammalian target of rapamycin pathway. Anticancer Drugs 2011; 22:463-467
6. Farag SS, Zhang S, Jansak BS,Wang X, Kraut E, Chan K, et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 2009; 33:1475-1480
7. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918
8. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22:2336-2347
9. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, et al. FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010; 15:428-435
10. Gallicchio MA, van Sinderen M, Bach LA. Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth. Horm Metab Res 2003; 35:822-827
11. Geoerger B, Kieran MW, Grupp S, SPerek D, Clancy J, Krygowski M, et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer 2012; 48:253-262
12. Coulter DW, Blatt J, D'Ercole AJ, Moats-Staats BM. IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. Anticancer Res 2008; 28:1509-1516
13. Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, et al. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol 2011; 29:2933-2940
14. Shu Q, Antalffy B, Su JM, Adesina A, Ou CN, Pietsch T, et al. Valproic acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res 2006; 12:4687-4694
15. Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A, Fru?hwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007; 120:1787-1794
16. Su JM, Li XN, Thompson P, Ingle AM, Ou CN, Ingle AM, Russell H, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: A children's oncology group report. Clin Cancer Res 2011; 17:589-597
17. Blaheta RA, Cinatl J Jr. Anti-Tumor mechanisms of valproate: A novel role for an old drug. Med Res Rev 2002; 22:492-51
18. Balsat M, Cornillon J. m-TOR inhibitors: Biology and use in the treatment of haematological diseases. Bull Cancer 2011; 98:935-943
19. Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011; 2011:830260
20. Wedel S, Hudak L, Seibel JM, Makarević J, Juengel E, Tsaur I, et al. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis 2011; 28: 479-491
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
22. Boni J, Leister C, Burns J, Burns J, Jordan R, Hoffmann M, et al. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications. J Clin Pharmacol 2007; 47:1430-1439
23. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, et al. Valproic acid (VPA) in patients with refractory advanced cancer: A dose escalating phase I clinical trial. Br J Cancer 2007; 97:177-182
24. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004; 63:S3-S8
25. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-6978
26. Mackenzie MJ, Ernst S, Johnson C, Winquist E. A phase I study of temsirolimus and metformin in advanced solid tumours. Invest New Drugs 2012; 30:647-652